Beyond virological suppression: The role of adherence in the late HAART era

Antiviral Therapy

Volumn 17, Issue 5, 2012, Pages 785-792

  Ammassari, Adriana ^a   Trotta, Maria Paola ^a   Shalev, Noga ^a,b   Marconi, Patrizia ^a   Antinori, Andrea ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PLACEBO; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; DISEASE CARRIER; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; MALE HOMOSEXUAL; METABOLIC DISORDER; MONOTHERAPY; OPPORTUNISTIC INFECTION; PAPILLOMAVIRUS INFECTION; PATIENT COMPLIANCE; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SEXUAL TRANSMISSION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS SHEDDING; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE MANAGEMENT; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE;

EID: 84865745185     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2084     Document Type: Review

References (60)

1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
2. Perno CF, Ceccherini-Silberstein F, De Luca A, et al. Virologic correlates of adherence to antiretroviral medications and therapeutic failure. J Acquir Immune Defic Syndr 2002; 31 Suppl 3:S118-S122.
3. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
4. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001; 33:1417-1423.
5. Ledergerber B, Cavassini M, Battegay M, et al. Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV Med 2011; 12:279-288.
6. Rosenblum M, Deeks SG, van der Laan M, Bangsberg DR. The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS ONE 2009; 4:e7196.
7. Lima VD, Bangsberg DR, Harrigan PR, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr 2010; 55:460-465.
8. Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother 2008; 61:769-773.
9. Gulick RM. Adherence to antiretroviral therapy: how much is enough? Clin Infect Dis 2006; 43:942-944.
10. Cohen CJ, Colson AE, Sheble-Hall AG, McLaughlin KA, Morse GD. Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. HIV Clin Trials 2007; 8:19-23.
11. Parienti JJ, Das-Douglas M, Massari V, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS ONE 2008; 3:e2783.
12. Braithwaite RS, Kozal MJ, Chang CC, et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS 2007; 21:1579-1589.
13. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 2007; 45:4-8.
14. Cohen MS, Gay C, Kashuba ADM, Blower S, Paxton L. Antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007; 146:591-601.
15. Edén A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 2010; 202:1819-1825.
16. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65:65-70.
17. Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010; 50:773-778.
18. Antinori A, Giancola ML, Grisetti S, et al. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. AIDS 2002; 16:1867-1876.
19. Ettenhofer ML, Foley J, Castellon SA, Hinkin CH. Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS. Neurology 2010; 74:1217-1222.
20. Cu-Uvin S, DeLong AK, Venkatesh KK, et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010; 24:2489-2497.
21. Graham SM, Masese L, Gitau R, et al. Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment. J Infect Dis 2010; 202:1538-1542.
22. Choudhury B, Pillay D, Taylor S, Cane PA. Analysis of HIV-1 variation in blood and semen during treatment and treatment interruption. J Med Virol 2002; 68:467-472.
23. Barroso PF, Schechter M, Gupta P, Bressan C, Bomfim A, Harrison LH. Adherence to antiretroviral therapy and persistence of HIV RNA in semen. J Acquir Immune Defic Syndr 2003; 32:435-440.
24. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Updated 14 October 2011. Accessed 15 April 2011.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
25. Minkoff H, Zhong Y, Burk RD, et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis 2010; 201:681-690.
26. Bernal A, Walters ST, Paulson RM, Mubasher M. Effect of patient adherence to antiretroviral therapy on the progression of cervical dysplasia among HIV-infected women. AIDS Read 2008; 18:382-385.
27. Paredes R, Lalama CM, Ribaudo HJ, et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010; 201:662-671.
28. Robbins GK, Daniels B, Zheng H, Chueh H, Meigs JB, Freedberg KA. Predictors of antiretroviral treatment failure in an urban HIV clinic. J Acquir Immune Defic Syndr 2007; 44:30-37.
29. Sizmann D, Glaubitz J, Simon CO, et al. Improved HIV-1 RNA quantitation by COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 using a novel dual-target approach. J Clin Virol 2010; 49:41-46.
30. Geretti AM, Smith C, Haberl A, et al. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther 2008; 13:927-936.
31. Mavigner M, Delobel P, Cazabat M, et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS ONE 2009; 4:e7658.
32. Havlir DV, Koelsch KK, Strain MC, et al. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J Infect Dis 2005; 191:1164-1168.
33. Eggena MP, Barugahare B, Jones N, et al. Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol 2005; 174:4407-4414.
34. Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H. Residual viraemia in HIV-1-infected patients with plasma viral load
35. Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7:e1000321.
36. + T cell response. J Infect Dis 2011; 203:960-968.
37. Taiwo B, Hicks C, Eron J. Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1. J Antimicrob Chemother 2010; 65:1100-1107.
38. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009; 23:279-291.
39. Arribas JR, Delgado R, Arranz A, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 2009; 51:147-152.
40. Pulido F, Pérez-Valero I, Delgado R, et al. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther 2009; 14:195-201.
41. Katlama C, Valantin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010; 24:2365-2374.
42. Arribas JR, Horbanb A, Gerstoftc J, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010; 24:223-230.
43. Vernazza P, Daneel S, Schiffer V, et al. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS 2007; 21:1309-1315.
44. Gutmann C, Cusini A, Günthard HF, et al. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 2010; 24:2347-2354.
45. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106.
46. Babafemi T, Summer Z, Sebastien G, et al. Results from a single arm study of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). 18th Conference on Retroviruses and Opportunistic Infections. 27 February - 2 March, 2011, Boston, MA, USA. Poster 551.
47. Cordery DV, Hesse K, Amin J, Cooper DA. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients. Antivir Ther 2010; 15:1035-1038.
48. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV- infected subjects. Patient Prefer Adherence. 2010; 4:115-125.
49. Weber J, Tatoud R, Fidler S. Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission. AIDS 2010; 24 Suppl 4:S27-S39.
50. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
51. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
52. Bentz L, Enel P, Dunais B, et al. Evaluating counseling outcome on adherence to prophylaxis and follow-up after sexual HIV-risk exposure: a randomized controlled trial. AIDS Care 2010; 22:1509-1516.
53. Lunding S, Katzenstein TL, Kronborg G, et al. The Danish PEP registry: experience with the use of postexposure prophylaxis (PEP) following sexual exposure to HIV from 1998 to 2006. Sex Transm Dis 2010; 37:49-52.
54. Lingappa JR, Hughes JP, Wang RS, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS ONE 2010; 5:e12598.
55. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092-2098.
56. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
57. Kalichman SC, Cherry C, Amaral CM, et al. Adherence to antiretroviral therapy and HIV transmission risks: implications for test-and-treat approaches to HIV prevention. AIDS Patient Care STDS 2010; 24:271-277.
58. Goldie SJ, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med 2001; 111:140-149.
59. Mannheimer SB, Morse E, Matts JP, et al. Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial. J Acquir Immune Defic Syndr 2006; 43 Suppl 1:S41-S47.
60. Trotta MP, Ammassari A, Melzi S, et al. Treatment-related factors and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2002; 31 Suppl 3:S128-S131.